Bipolar Disorder (2018) |
1.33 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FNDC4 |
Bipolar Disorder or Schizophrenia |
1.06 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATP13A1 NTN5 |
Intelligence (Savage-Jansen 2018) |
1.11 |
4 |
0 |
0.0 |
-0.72 |
2.8e-01 |
AMIGO1 ATXN7L2 DDX56 TXNL4B |
Neuroticism (Nagel 2018) |
0.67 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SLC22A1 |
Schizophrenia (2018) |
0.97 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATP13A1 |
Schizophrenia vs Biploar Disorder |
1.01 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FNDC4 |
Alzheimer’s Disease (in mother) |
8.32 |
8 |
8 |
17.8 |
0.93 |
7.4e-04 |
APOC2 APOC4 BCAM CEACAM16 PVRL2 TOMM40 ZNF229 ZNF285 |
Alzheimer’s Disease (in father) |
3.69 |
6 |
3 |
6.7 |
0.96 |
2.9e-03 |
APOC2 APOC4 PVRL2 TOMM40 ZNF229 ZNF285 |
Alzheimer’s Disease (including proxy) |
15.08 |
8 |
8 |
17.8 |
0.92 |
1.3e-03 |
APOC2 APOC4 BCAM CEACAM16 PVRL2 TOMM40 ZNF229 ZNF285 |
Crohns Disease (2017) |
1.29 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
DOCK7 FNDC4 NTN5 |
Irritable Bowel Disease (IBD) |
1.13 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 |
Ulcerative Colitis (UC) |
1.01 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RGS19 |
Reaction Time |
0.94 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SMARCA4 |
Verbal and Numeric Reasoning (VNR) |
1.14 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATXN7L2 |
Breast Cancer |
1.44 |
4 |
1 |
2.2 |
0.42 |
5.8e-01 |
ABO ATP13A1 RGS19 SIDT2 |
Ovarian Cancer |
1.60 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
C12orf27 CARM1 |
Coronary Artery Disease (CAD) |
5.97 |
8 |
3 |
6.7 |
0.95 |
7.6e-05 |
ATXN7L2 C12orf27 CELSR2 LPL PSRC1 SLC22A3 ST3GAL4 ZNF259 |
Crohns Disease (2012) |
1.06 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
DOCK7 |
Fasting Glucose |
2.18 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 |
HbA1C |
1.18 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ABO |
HDL Cholesterol |
10.20 |
14 |
6 |
13.3 |
-0.49 |
6.5e-02 |
ABCA1 APOB APOC2 BUD13 CARM1 CELSR2 GPSM2 LPL PIGV PVRL2 RAB3IL1 SIDT2 TOMM40 ZNF259 |
LDL Cholesterol |
50.39 |
53 |
39 |
86.7 |
0.95 |
2.7e-34 |
ABCA1 ABCG5 ABO AMIGO1 APOB APOC2 APOC4 ATP13A1 ATXN7L2 BCAM BUD13 C12orf27 C12orf43 CARM1 CEACAM16 CELSR2 DDX56 DHODH DHX38 DNAH11 DOCK7 FNDC4 GPSM2 GSTM1 HMGCR HP KANK2 LRPPRC MKRN2 MRPL45P2 N4BP2L1 NPC1L1 NTN5 PAFAH1B2 PCSK7 PIGV PSRC1 PVRL2 RAB3IL1 RGS12 RP11-288H12.3 SIDT2 SLC22A3 SMARCA4 SPC24 ST3GAL4 TOMM40 TSEN2 TXNL4B ZHX3 ZNF229 ZNF259 ZNF285 |
Rheumatoid Arthritis |
1.66 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RGS19 |
Schizophrenia (2014) |
0.94 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATP13A1 |
Triglycerides |
31.08 |
16 |
13 |
28.9 |
0.82 |
6.5e-06 |
APOB ATP13A1 BUD13 DOCK7 FNDC4 LPL NAT2 PAFAH1B2 PCSK7 PVRL2 RGS12 SIDT2 SIK3 SLC22A3 TXNL4B ZNF259 |
Blood Eosinophil Count |
1.48 |
16 |
10 |
22.2 |
-0.43 |
7.2e-02 |
ABO APOC2 ATP13A1 BCAM C12orf27 CARM1 LPL MRPL38 PAFAH1B2 PIGV SIDT2 SMARCA4 ST3GAL4 TOMM40 TSEN2 ZNF259 |
Blood Platelet Count |
2.84 |
27 |
21 |
46.7 |
-0.23 |
2.0e-01 |
ABO APOC2 ATP13A1 BUD13 C12orf27 C12orf43 CARM1 DDX56 DOCK7 FNDC4 GSTM1 HMGCR HP NTN5 PAFAH1B2 PCSK7 PIGV RAB3IL1 RGS12 SIDT2 SIK3 TOMM40 TSEN2 TXNL4B ZHX3 ZNF259 ZNF285 |
Blood Red Count |
2.49 |
12 |
9 |
20.0 |
-0.29 |
3.6e-01 |
ABCG5 ABO ATP13A1 C12orf27 DHODH FNDC4 HP MKRN2 PCSK7 PVRL2 TXNL4B ZHX3 |
Blood White Count |
1.50 |
11 |
4 |
8.9 |
0.08 |
8.0e-01 |
ABO ATP13A1 CARM1 DOCK7 FNDC4 MRPL38 PAFAH1B2 PVRL2 SMARCA4 TMEM133 TSEN2 |
Heel T-Score |
0.87 |
9 |
4 |
8.9 |
-0.56 |
1.1e-01 |
ABO ATP13A1 ATXN7L2 CELSR2 HP PCSK7 TMEM133 TSEN2 ZHX3 |
BMI |
1.66 |
14 |
6 |
13.3 |
-0.33 |
2.1e-01 |
AMIGO1 ATXN7L2 CEACAM16 DHODH DHX38 FNDC4 HMGCR HP MRPL38 NOP58 RGS12 SIDT2 SLC22A3 TXNL4B |
Height |
1.19 |
26 |
18 |
40.0 |
-0.63 |
8.9e-05 |
ABCG5 ABO APOC2 APOC4 ATP13A1 C12orf27 CELSR2 FNDC4 GPSM2 KANK2 LPL MKRN2 MRPL45P2 NOP58 NTN5 PIGV PSRC1 RAB3IL1 RGS12 SLC22A3 SMARCA4 SPC24 TMEM133 TSEN2 ZNF229 ZNF259 |
Waist Hip Ratio (WHR) |
2.37 |
15 |
7 |
15.6 |
0.66 |
2.9e-03 |
ABCA1 ATP13A1 BUD13 CARM1 KANK2 LPL LRPPRC MKRN2 NTN5 RGS19 SIDT2 SLC22A3 SMARCA4 TSEN2 ZHX3 |
Systolic Blood Pressure |
2.68 |
14 |
8 |
17.8 |
0.80 |
3.5e-04 |
APOC4 FNDC4 MRPL38 NTN5 PAFAH1B2 PCSK7 PIGV RGS12 RGS19 SIDT2 SMARCA4 ST3GAL4 TMEM133 TOMM40 |
Smoking Status |
1.29 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
C12orf43 DHX38 |
Allergy or Eczema |
1.28 |
5 |
1 |
2.2 |
0.32 |
5.9e-01 |
ABO C12orf27 C12orf43 FNDC4 PVRL2 |
Cardiovascular Disease |
8.55 |
43 |
30 |
66.7 |
0.94 |
9.6e-25 |
APOB APOC4 ATXN7L2 BCAM BUD13 C12orf27 CELSR2 DDX56 DHODH DHX38 DOCK7 FNDC4 HMGCR HP LPL MRPL38 MRPL45P2 NAT2 NOP58 NPC1L1 NTN5 PAFAH1B2 PCSK7 PIGV PSRC1 PVRL2 RGS12 RGS19 RP11-288H12.3 SIDT2 SIK3 SLC22A1 SLC22A3 SMARCA4 SPC24 TMEM133 TOMM40 TSEN2 TXNL4B UBXN2B ZNF229 ZNF259 ZNF285 |
Hypothyroidism (self reported) |
1.27 |
4 |
1 |
2.2 |
0.27 |
7.3e-01 |
DDX56 NTN5 RGS12 SIK3 |
Respiratory disease |
1.31 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
ABO MRPL38 |
Type 2 Diabetes (T2D) (2018) |
2.08 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
ATP13A1 FNDC4 LPL |
Lung FEV1/FVC ratio |
0.96 |
6 |
3 |
6.7 |
0.12 |
8.3e-01 |
CELSR2 HP NTN5 PSRC1 SIK3 TMEM133 |
Lung FVC |
1.15 |
8 |
4 |
8.9 |
-0.65 |
7.9e-02 |
ABO NOP58 PVRL2 RAB3IL1 RGS12 RGS19 SIDT2 SIK3 |
Neuroticism |
0.73 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
AMIGO1 |
Chronotype (morning person) |
1.23 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
AMIGO1 ZNF285 |
Hair Pigment |
0.22 |
8 |
2 |
4.4 |
0.64 |
3.4e-02 |
C12orf43 DHX38 FNDC4 MKRN2 PIGV SIDT2 SMARCA4 TMEM133 |
Tanning |
0.23 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 |
Hand grip strength (left) |
1.09 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PVRL2 |
Number of treatments/medications taken |
3.27 |
8 |
1 |
2.2 |
0.92 |
5.2e-04 |
CELSR2 DHX38 FNDC4 HP NOP58 NTN5 PSRC1 TMEM133 |
Sensitivity / hurt feelings |
0.92 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATP13A1 |
Relative age of first facial hair |
1.24 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 |
Systolic blood pressure, automated reading |
1.85 |
4 |
2 |
4.4 |
0.81 |
1.9e-01 |
PIGV RGS19 ST3GAL4 TMEM133 |
Angina |
5.16 |
10 |
2 |
4.4 |
0.94 |
6.6e-06 |
ABCG5 ATXN7L2 CELSR2 LPL PSRC1 RGS19 SLC22A1 SLC22A3 SPC24 TMEM133 |
Medication: Metformin |
1.85 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 LPL |
Diabetes (father) |
1.42 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FNDC4 |
Diabetes (mother) |
1.78 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATP13A1 PVRL2 |
Impedance of leg (right) |
1.24 |
8 |
6 |
13.3 |
0.37 |
3.3e-01 |
ABO AMIGO1 ATP13A1 ATXN7L2 FNDC4 HMGCR RGS19 TMEM133 |
Leg fat-free mass (left) |
1.56 |
9 |
5 |
11.1 |
-0.82 |
7.4e-03 |
APOC4 ATP13A1 ATXN7L2 CARM1 FNDC4 HMGCR MRPL38 SLC22A3 SMARCA4 |
Trunk fat percentage |
1.33 |
9 |
2 |
4.4 |
-0.18 |
6.5e-01 |
C12orf43 DHX38 GSTM1 HMGCR MRPL38 NOP58 PVRL2 SLC22A3 TXNL4B |
Hand grip strength (right) |
1.06 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PVRL2 |
Relative age voice broke |
1.20 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
C12orf27 |
Age when periods started (menarche) |
1.05 |
4 |
0 |
0.0 |
-0.48 |
5.2e-01 |
C12orf27 C12orf43 NOP58 NTN5 |
Heel bone mineral density (BMD) T-score, automated (left) |
0.78 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ABO |
High blood pressure |
2.43 |
6 |
3 |
6.7 |
0.91 |
1.2e-02 |
MRPL38 NPC1L1 NTN5 PIGV RGS19 TMEM133 |
Hayfever, allergic rhinitis or eczema |
1.21 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PVRL2 |
Medication: Atenolol |
2.54 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TMEM133 |
Sitting height |
0.96 |
12 |
2 |
4.4 |
-0.49 |
1.1e-01 |
ABCG5 ABO AMIGO1 ATP13A1 FNDC4 KANK2 MRPL45P2 NTN5 RGS12 SLC22A3 SPC24 TXNL4B |
High blood pressure (mother) |
1.37 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
PIGV TMEM133 |
Body mass index (BMI) |
1.42 |
7 |
2 |
4.4 |
-0.26 |
5.7e-01 |
DHX38 FNDC4 GSTM1 HMGCR HP PVRL2 TXNL4B |
Impedance of leg (left) |
1.35 |
9 |
6 |
13.3 |
0.40 |
2.5e-01 |
ABO AMIGO1 ATP13A1 ATXN7L2 CARM1 FNDC4 HMGCR RGS19 TMEM133 |
Leg predicted mass (left) |
1.57 |
9 |
5 |
11.1 |
-0.82 |
7.4e-03 |
APOC4 ATP13A1 ATXN7L2 CARM1 FNDC4 HMGCR MRPL38 SLC22A3 SMARCA4 |
Trunk fat mass |
1.38 |
8 |
3 |
6.7 |
-0.25 |
5.5e-01 |
C12orf43 DHX38 GSTM1 HMGCR MRPL38 PVRL2 SLC22A3 TXNL4B |
Waist circumference |
1.37 |
6 |
1 |
2.2 |
-0.29 |
5.7e-01 |
DHX38 FNDC4 HMGCR HP PVRL2 TXNL4B |
Number of incorrect matches in round |
0.88 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
NAT2 |
Nervous feelings |
0.98 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
C12orf43 |
Had menopause |
1.12 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
LPL |
Had other major operations |
1.12 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ABCG5 |
Forced vital capacity (FVC) |
1.21 |
7 |
4 |
8.9 |
-0.55 |
2.1e-01 |
ABO NOP58 PVRL2 RGS12 SIK3 SMARCA4 TMEM133 |
Heel bone mineral density (BMD) T-score, automated (right) |
0.87 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ABO |
Mouth/teeth dental problems |
0.89 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
NTN5 |
Heart attack |
4.15 |
6 |
2 |
4.4 |
0.93 |
8.1e-03 |
CELSR2 LPL PSRC1 SLC22A1 SLC22A3 SPC24 |
Allergy |
1.28 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
ABO C12orf27 |
Diabetes (self-reported) |
1.82 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 |
Medication: Ramipril |
2.25 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
TMEM133 |
Medication: Simvastatin |
17.26 |
40 |
24 |
53.3 |
0.99 |
4.6e-38 |
ABCG5 ABO AMIGO1 APOB APOC2 ATP13A1 ATXN7L2 BCAM CELSR2 DHODH DHX38 DOCK7 FNDC4 GPSM2 GSTM1 HMGCR HP LPL LRPPRC MRPL45P2 NAT2 NOP58 NPC1L1 NTN5 PAFAH1B2 PCSK7 PIGV PSRC1 PVRL2 RAB3IL1 RGS19 SLC22A3 SMARCA4 SPC24 ST3GAL4 TMEM133 TOMM40 TXNL4B ZHX3 ZNF259 |
Illnesses of siblings |
2.28 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TMEM133 |
Weight |
1.51 |
12 |
3 |
6.7 |
-0.66 |
2.0e-02 |
APOC4 ATXN7L2 CARM1 DHX38 FNDC4 GSTM1 HMGCR MRPL38 NTN5 SLC22A3 SMARCA4 TXNL4B |
Impedance of arm (right) |
1.19 |
7 |
3 |
6.7 |
0.79 |
3.4e-02 |
ATXN7L2 FNDC4 HMGCR KANK2 MRPL45P2 NTN5 UBXN2B |
Arm fat percentage (right) |
1.54 |
9 |
4 |
8.9 |
0.07 |
8.4e-01 |
ABO DHX38 GSTM1 HMGCR HP MRPL38 NOP58 SIDT2 TXNL4B |
Trunk fat-free mass |
1.62 |
9 |
7 |
15.6 |
-0.88 |
1.6e-03 |
APOC4 ATXN7L2 CELSR2 FNDC4 HMGCR NTN5 SLC22A3 SMARCA4 TMEM133 |
Hip circumference |
1.62 |
11 |
5 |
11.1 |
-0.64 |
2.5e-02 |
ABCA1 CARM1 FNDC4 GSTM1 HMGCR MRPL38 NTN5 SLC22A3 SMARCA4 TSEN2 TXNL4B |
Alcohol intake versus 10 years previously |
2.27 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
AMIGO1 FNDC4 NTN5 |
Father's age at death |
2.54 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATXN7L2 CELSR2 LPL |
Forced expiratory volume in 1-second (FEV1) |
1.13 |
5 |
1 |
2.2 |
-0.47 |
4.3e-01 |
ABO PVRL2 RGS12 SMARCA4 TMEM133 |
Pulse rate |
1.67 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 |
Qualifications: A levels/AS levels or equivalent |
0.94 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
C12orf43 RGS12 |
Serious illness, injury or assault of a close relative in last 2 years |
1.58 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
NTN5 |
Mouth/teeth dental problems: Dentures |
0.92 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
NTN5 |
Asthma |
1.22 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
MRPL38 SMARCA4 |
Medication: Cholesterol lowering |
21.80 |
48 |
30 |
66.7 |
0.99 |
6.7e-48 |
ABCG5 ABO AMIGO1 APOB APOC2 ATP13A1 ATXN7L2 BCAM BUD13 C12orf27 CEACAM16 CELSR2 DHODH DHX38 DOCK7 FNDC4 GPSM2 GSTM1 HMGCR HP KANK2 LPL LRPPRC MRPL45P2 NAT2 NOP58 NPC1L1 NTN5 PAFAH1B2 PCSK7 PIGV PSRC1 PVRL2 RGS19 RP11-288H12.3 SIDT2 SLC22A1 SLC22A3 SMARCA4 SPC24 ST3GAL4 TMEM133 TOMM40 TXNL4B UBXN2B ZHX3 ZNF229 ZNF259 |
Forced expiratory volume in 1-second (FEV1), Best measure |
1.10 |
5 |
1 |
2.2 |
-0.48 |
4.2e-01 |
ABO PVRL2 RGS12 SMARCA4 TMEM133 |
Impedance of arm (left) |
1.22 |
5 |
3 |
6.7 |
0.80 |
1.0e-01 |
ATXN7L2 FNDC4 HMGCR KANK2 UBXN2B |
Arm fat mass (right) |
1.55 |
8 |
2 |
4.4 |
-0.23 |
5.8e-01 |
DHX38 FNDC4 GSTM1 HMGCR HP MRPL38 SLC22A3 TXNL4B |
Trunk predicted mass |
1.62 |
9 |
7 |
15.6 |
-0.88 |
1.6e-03 |
APOC4 ATXN7L2 CELSR2 FNDC4 HMGCR NTN5 SLC22A3 SMARCA4 TMEM133 |
Standing height |
1.20 |
18 |
12 |
26.7 |
-0.59 |
4.8e-03 |
ABCG5 APOC2 APOC4 ATP13A1 CELSR2 FNDC4 KANK2 MKRN2 MRPL45P2 NOP58 NTN5 PIGV PSRC1 RGS12 SLC22A3 SMARCA4 SPC24 TSEN2 |
Hair/balding pattern: Pattern 4 |
0.73 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ZHX3 |
Birth weight of first child |
1.89 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATP13A1 HP RGS19 |
Peak expiratory flow (PEF) |
1.05 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
ABO NTN5 |
Blood clot in the leg (DVT) |
1.99 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ABO |
Medication for cholesterol, blood pressure or diabetes |
8.97 |
24 |
8 |
17.8 |
-0.95 |
1.0e-13 |
APOB ATXN7L2 BUD13 CELSR2 DHX38 FNDC4 HMGCR HP LPL LRPPRC NPC1L1 NTN5 PAFAH1B2 PCSK7 PSRC1 RGS19 SIDT2 SIK3 SLC22A1 SPC24 TMEM133 TOMM40 TXNL4B ZNF259 |
Gout (self-reported) |
2.38 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 |
Hypothyroidism/myxoedema (self-reported) |
1.23 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SIK3 |
Medication: Amlodipine |
1.47 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
TMEM133 |
Birth weight |
1.26 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
NTN5 |
Chronic bronchitis/emphysema (mother) |
1.16 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
BCAM |
High blood pressure (siblings) |
1.84 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TMEM133 |
Forced vital capacity (FVC), Best measure |
1.28 |
6 |
3 |
6.7 |
-0.68 |
1.3e-01 |
ABO NOP58 PVRL2 RGS12 SIK3 SMARCA4 |
Body fat percentage |
1.40 |
10 |
2 |
4.4 |
-0.02 |
9.6e-01 |
BCAM C12orf43 DHX38 GSTM1 HMGCR HP MRPL38 NOP58 PVRL2 TXNL4B |
Leg fat percentage (right) |
1.39 |
6 |
1 |
2.2 |
0.16 |
7.6e-01 |
DHX38 GSTM1 HMGCR HP KANK2 NOP58 |
Arm fat-free mass (right) |
1.51 |
8 |
6 |
13.3 |
-0.89 |
3.0e-03 |
APOC4 ATXN7L2 CELSR2 FNDC4 HMGCR NTN5 SLC22A3 SMARCA4 |
Comparative body size at age 10 |
1.04 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATP13A1 NTN5 |
Worry too long after embarrassment |
0.78 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RGS12 |
Health satisfaction |
1.07 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
GPSM2 |
Qualifications: College or University degree |
0.93 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
ATXN7L2 DNAH11 RGS12 |
Medication: Blood pressure |
2.42 |
4 |
1 |
2.2 |
0.93 |
7.0e-02 |
NPC1L1 NTN5 RGS19 TMEM133 |
Angina (self-reported) |
5.48 |
9 |
4 |
8.9 |
0.95 |
3.3e-06 |
ABCG5 ATXN7L2 CELSR2 LPL PSRC1 RGS19 SLC22A1 SLC22A3 SPC24 |
Medication: Allopurinol |
2.15 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 PIGV |
Medication: Omeprazole |
1.22 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
DNAH11 |
Heart disease (mother) |
2.99 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
SLC22A1 SLC22A3 |
Whole body fat mass |
1.41 |
7 |
3 |
6.7 |
-0.46 |
3.0e-01 |
DHX38 GSTM1 HMGCR MRPL38 PVRL2 SLC22A3 TXNL4B |
Leg fat mass (right) |
1.45 |
8 |
1 |
2.2 |
-0.25 |
5.5e-01 |
DHX38 FNDC4 GSTM1 HMGCR HP MRPL38 SLC22A3 TXNL4B |
Arm predicted mass (right) |
1.47 |
8 |
5 |
11.1 |
-0.89 |
3.0e-03 |
APOC4 ATXN7L2 CELSR2 FNDC4 HMGCR NTN5 SLC22A3 SMARCA4 |
Pulse rate, automated reading |
1.69 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 KANK2 |
Alcohol intake frequency. |
2.11 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
FNDC4 NTN5 RGS12 |
Comparative height size at age 10 |
1.48 |
12 |
5 |
11.1 |
-0.51 |
7.5e-02 |
APOC4 ATP13A1 C12orf27 CELSR2 FNDC4 KANK2 MKRN2 NTN5 PIGV RGS12 SLC22A3 SPC24 |
Chest pain or discomfort |
1.53 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MRPL45P2 |
Medication: Aspirin |
3.93 |
7 |
1 |
2.2 |
0.90 |
2.6e-03 |
ATXN7L2 CELSR2 LPL PSRC1 RGS19 SLC22A1 SLC22A3 |
Hypertension (Self-reported) |
2.45 |
5 |
4 |
8.9 |
0.89 |
4.3e-02 |
MRPL38 NTN5 PIGV RGS19 TMEM133 |
Illnesses of father: Heart disease |
6.06 |
10 |
5 |
11.1 |
0.94 |
2.3e-06 |
CELSR2 LPL NPC1L1 PSRC1 RGS19 RP11-288H12.3 SLC22A1 SLC22A3 SPC24 ST3GAL4 |
Whole body fat-free mass |
1.58 |
10 |
6 |
13.3 |
-0.82 |
3.8e-03 |
APOC4 ATP13A1 ATXN7L2 CELSR2 FNDC4 HMGCR NTN5 SLC22A3 SMARCA4 TMEM133 |
Leg fat-free mass (right) |
1.57 |
9 |
6 |
13.3 |
-0.76 |
1.1e-02 |
APOC4 ATP13A1 ATXN7L2 FNDC4 HMGCR MRPL38 SLC22A3 SMARCA4 TMEM133 |
Arm fat percentage (left) |
1.53 |
10 |
4 |
8.9 |
-0.04 |
9.0e-01 |
ABO DHX38 GSTM1 HMGCR HP MRPL38 NOP58 PVRL2 SIDT2 TXNL4B |
Mood swings |
1.01 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
AMIGO1 |
Diabetes diagnosed by doctor |
1.94 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
ATP13A1 FNDC4 |
Medication for cholesterol |
5.76 |
13 |
2 |
4.4 |
-0.92 |
1.6e-06 |
CELSR2 DHODH DHX38 FNDC4 GPSM2 HP NTN5 PCSK7 PIGV PSRC1 PVRL2 TMEM133 TXNL4B |
Back pain experienced in last month |
1.39 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
APOB |
Asthma (self-reported) |
1.21 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MRPL38 |
Osteoarthritis (self-reported) |
1.93 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SMARCA4 |
Medication: Aspirin |
4.19 |
7 |
1 |
2.2 |
0.89 |
2.9e-03 |
ATXN7L2 CELSR2 LPL PSRC1 RGS19 SLC22A1 SLC22A3 |
Illnesses of father: None of the above (group 1) |
2.30 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SLC22A3 |
Forced expiratory volume in 1-second (FEV1), predicted percentage |
1.39 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PVRL2 |
Whole body water mass |
1.57 |
10 |
6 |
13.3 |
-0.81 |
4.1e-03 |
APOC4 ATP13A1 ATXN7L2 CELSR2 FNDC4 HMGCR NTN5 SLC22A3 SMARCA4 TMEM133 |
Leg predicted mass (right) |
1.56 |
9 |
5 |
11.1 |
-0.76 |
1.1e-02 |
APOC4 ATP13A1 ATXN7L2 FNDC4 HMGCR MRPL38 SLC22A3 SMARCA4 TMEM133 |
Arm fat mass (left) |
1.53 |
8 |
2 |
4.4 |
-0.23 |
5.9e-01 |
DHX38 FNDC4 GSTM1 HMGCR HP MRPL38 SLC22A3 TXNL4B |
Number of self-reported non-cancer illnesses |
3.31 |
4 |
1 |
2.2 |
0.98 |
1.8e-02 |
DHX38 FNDC4 NTN5 RGS19 |
Medication: Blood pressure |
2.44 |
5 |
2 |
4.4 |
0.91 |
1.2e-02 |
DHX38 HP PIGV RGS19 TMEM133 |
Medication: Bendroflumethiazide |
1.49 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
PIGV TMEM133 |
Medication: Lisinopril |
1.18 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TMEM133 |
Medication: Atorvastatin |
16.31 |
34 |
14 |
31.1 |
0.98 |
1.1e-28 |
ABCA1 ABO APOB ATP13A1 ATXN7L2 BCAM BUD13 C12orf27 C12orf43 CARM1 CELSR2 DOCK7 FNDC4 GPSM2 HMGCR KANK2 LPL LRPPRC PAFAH1B2 PCSK7 PSRC1 PVRL2 RGS19 SIK3 SLC22A1 SLC22A3 SMARCA4 SPC24 TOMM40 TXNL4B UBXN2B ZNF229 ZNF259 ZNF285 |
Basal metabolic rate |
1.54 |
9 |
6 |
13.3 |
-0.82 |
6.5e-03 |
APOC4 ATP13A1 ATXN7L2 CELSR2 FNDC4 HMGCR NTN5 SLC22A3 SMARCA4 |
Leg fat percentage (left) |
1.36 |
7 |
1 |
2.2 |
-0.04 |
9.4e-01 |
BCAM DHX38 GSTM1 HMGCR HP KANK2 NOP58 |
Arm fat-free mass (left) |
1.47 |
8 |
7 |
15.6 |
-0.89 |
3.2e-03 |
APOC4 ATXN7L2 CELSR2 FNDC4 HMGCR NTN5 SLC22A3 SMARCA4 |
Number of operations (self-reported) |
0.87 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ABCG5 |
Irritability |
0.89 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATP13A1 |
Diastolic blood pressure, automated reading |
1.80 |
4 |
1 |
2.2 |
0.18 |
8.2e-01 |
ABO PIGV RGS19 TMEM133 |
Myopia |
1.46 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
KANK2 |
Vascular/heart problems diagnosed by doctor |
2.77 |
6 |
3 |
6.7 |
-0.92 |
9.6e-03 |
MRPL38 NPC1L1 NTN5 PIGV RGS19 TMEM133 |
Cholesterol lowering medication |
19.21 |
46 |
27 |
60.0 |
0.99 |
1.0e-46 |
ABCA1 ABCG5 ABO AMIGO1 APOB APOC2 ATXN7L2 BCAM BUD13 C12orf27 C12orf43 CELSR2 DHODH DHX38 DOCK7 FNDC4 GPSM2 HMGCR HP KANK2 LPL LRPPRC N4BP2L1 NAT2 NOP58 NPC1L1 NTN5 PAFAH1B2 PCSK7 PIGV PSRC1 PVRL2 RAB3IL1 RGS19 SIDT2 SIK3 SLC22A3 SMARCA4 SPC24 TOMM40 TSEN2 TXNL4B ZHX3 ZNF229 ZNF259 ZNF285 |
Medication: Omeprazole (e.g. Zanprol) |
1.15 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
DNAH11 |
Heart attack/myocardial infarction (self-reported) |
4.09 |
7 |
2 |
4.4 |
0.93 |
2.5e-03 |
CELSR2 LPL PSRC1 SLC22A1 SLC22A3 SP4 SPC24 |
Deep venous thrombosis (DVT) (self-reported) |
1.85 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ABO |
Heart disease (siblings) |
3.32 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
SLC22A1 SLC22A3 |
Impedance of whole body |
1.19 |
7 |
4 |
8.9 |
0.76 |
4.8e-02 |
AMIGO1 ATP13A1 ATXN7L2 FNDC4 HMGCR RGS19 TMEM133 |
Leg fat mass (left) |
1.43 |
8 |
1 |
2.2 |
-0.27 |
5.1e-01 |
DHX38 FNDC4 GSTM1 HMGCR HP MRPL38 SLC22A3 TXNL4B |
Arm predicted mass (left) |
1.55 |
8 |
7 |
15.6 |
-0.90 |
2.5e-03 |
APOC4 ATXN7L2 CELSR2 FNDC4 HMGCR NTN5 SLC22A3 SMARCA4 |